Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Tucatinib improves PFS, OS in HER2+ breast cancer with brain metastases

Key clinical point: Adding tucatinib to trastuzumab and capecitabine improved survival in patients with HER2-positive breast cancer and brain metastasis.

Major finding: The median overall survival was 18.1 months in the tucatinib arm and 12 months in patients who received only trastuzumab and capecitabine (P = .005).

Study details: Analysis of data from the phase 2 HER2CLIMB trial, limited to the 291 women with brain metastases at baseline.

Disclosures: The research was funded by tucatinib’s maker, Seattle Genetics. Investigators disclosed financial relationships with Seattle Genetics, including employment.


Lin NU et al. ASCO 2020, Abstract 1005.